Anaxyl 500 mg/5 ml (IM/IV Injection)
5 ml ampoule: ৳ 50.34 (1 x 5: ৳ 251.70)
Medicine Details
| Category | Details |
|---|---|
| Generic | Tranexamic acid |
| Company | Aci limited |
| Also available as |
Title
- Anaxyl Oral Solution
Categories
- Medicine
- Hemostatic Drugs
- Anti-fibrinolytic Drugs
Description
- A preparation of tranexamic acid (trans-4 aminomethyl-cyclohexanecarboxylic acid) used for prophylaxis and therapy of various hemorrhagic conditions in medicine, surgery, urology, obstetrics, otorhinolaryngology, stomatology, and oncology.
Color Options
- Clear liquid
Dimensions
- Available in various bottle sizes
Material
- Tranexamic Acid
Dosage Form
- Oral Solution
Dosage Strength
- 500 mg
- 1000 mg
Recommended Daily Dose
- 500-1000 mg 3 times daily for adults
- 5-10 mg orally administered daily in divided doses for children
Route of Administration
- Oral
- Intravenous
- Intramuscular
Age Group
- Suitable for adults and children
Pharmacology
- Strong antifibrinolytic action
- Effective inhibition of plasminogen activation
- Low acute and chronic toxicity
- Well absorbed by oral route
- Excreted mainly by renal route
Onset of Action
- 15-30 minutes after administration
Duration of Effect
- More lasting effect compared to conventional hemostatics
Interactions
- Incompatible with solutions containing penicillins
- Antagonized by thrombolytic drugs like Streptokinase & Urokinase
- Potential for thrombus formation increased by estrogen-containing drugs
Contraindications
- Known hypersensitivity to the product
- Thromboembolic disease
- Arterial and venous thrombosis
- Endocavitary hemorrhages
- Serious kidney failure
Side Effects
- Fatigue
- Conjunctival irritation
- Nasal blockage
- Itching
- Skin reddening
- Exanthems
- Nausea
- Diarrhea
- Gastric pyrosis
- Postural hypotension
Pregnancy & Lactation
- Not recommended during known and presumed pregnancy
- Low transplacental passage
- Unlikely antifibrinolytic effect in infants
Precautions & Warnings
- Use in hyperfibrinolysis cases
- Prophylactic treatment must begin 24 hours before operation
- Prolong therapy of hemorrhages for at least 24 hours after manifestations have disappeared
- Reduce doses in hematuria to prevent clot formation in urinary tract
- Avoid use in serious renal insufficiency or anuric syndromes
- Exercise caution in renal dysfunction, cardiopathic, and hepatopathic subjects
Therapeutic Class
- Haemostatic Drugs
- Anti-fibrinolytic Drugs
Storage Conditions
- Store in a dry place at 15-30°C
- Away from light
- Keep out of children's reach